13.06.2022 Gerresheimer AG  DE000A0LD6E6

Gerresheimer AG: Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease


 


DGAP-Media / 13.06.2022 / 10:00

Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease

  • Partners join forces to improve lives of millions of Parkinson’s patients worldwide with a transformative technology-based solution
  • Gerresheimer participates in seed-round of the Finnish MedTech company and university spin-off
  • Monitoring and personalized medication adjustment in combination is a novum

Duesseldorf/Kuopio, June 13, 2022 – Gerresheimer AG and the Finnish MedTech start-up Adamant Health Oy partner up to develop a life-changing solution for millions of people worldwide suffering from Parkinson’s disease. The measuring technology and platform in development will address one of the biggest impediments in treating symptoms of Parkinson’s: Determining the optimal time to take symptom suppressing medication. In the future, Adamant Health’s measurement and analysis technology and Gerresheimer’s digital platform solution will help to determine the exact right moment for drug administration and inform patients as well as medical staff about the patient’s treatment and symptom development. The advantage for patients: The symptoms become much more stable and predictable. This allows them to live their everyday lives in a more independent, safe and satisfying way.

“Our common goal is to optimize the treatment of Parkinson’s and to improve the patient’s quality of life dramatically,” said Dietmar Siemssen, CEO Gerresheimer AG. “The investment is part of our strategic expansion into personalized drug delivery devices combined with platform-based and digital disease monitoring. It will also complement our high value solution offering for clients as defined in our strategy process formula G”, he added.

Parkinson's disease is a progressive nervous system disorder and causes reoccurring tremors, stiffness and slowing of movement. While it currently is incurable, medication can significantly alleviate symptoms. The disease affects approximately 10 million patients worldwide.

“We are expecting the number of people with Parkinson’s to more than double within the next 30 years,” said Paulus Carpelan, CEO Adamant Health Oy. “Our measurement and analysis service with its unique technologies aim to help individualizing therapies and consequently to improve patients’ quality of life significantly,” he added.

Adamant Health is a start-up firm and a spinoff from the University of Eastern Finland. It aims at revolutionizing Parkinson’s therapy based on 15 years of academic research expertise. The company applies scientific insights to the individual analysis of neuromuscular function and motion.

Gerresheimer has participated in the seed round at Adamant Health and is a major industry partner in this round.

By partnering up, Gerresheimer and Adamant Health fill a gap in the therapy of Parkinson’s patients. A combination of monitoring and personalized adjustment of medication is a novelty. In the field of monitoring of the neurodegenerative chronic disease, Adamant Health already holds a unique position: The current technologies used in monitoring disease progression only collects patient’s physical movement data. The sensor used in Adamant Health’s solution links this function with technology called surface electromyography (EMG), i.e., the local measurement of electrical neuromuscular activity.

Parkinson’s disease is caused by the death of certain nerve cells in the brain. This leads to a deficiency of the neurotransmitter dopamine. Among other things, dopamine plays a major role in controlling muscle function – and thus movement. The aim of drug treatment is to normalize the concentration of this neurotransmitter. To achieve this, the medication must be precisely set and adjusted at regular intervals. This is made possible by micropumps such as the D-Mine pump from Gerresheimer.

Adamant Health’s technology is intended for wide use for the benefit of all people suffering from Parkinson’s disease, medication development as well as research. With the partnership, the aim is to combine this technology with personalized medical treatment solutions, such as the existing pump manufactured by Gerresheimer and beyond that make it accessible to all Parkinson patients. This allows the real-time collection and analysis of data and a precise and continuous drug application adjustment at home. A solution, which will significantly improve the lives of millions of affected people.

Contact Press
Ueli Utzinger
Group Senior Director Marketing & Communication
T +49 211 6181-250
[email protected]

Contact Investor Relations
Carolin Nadilo
Corporate Senior Director Investor Relations
T +49 211 6181-220
[email protected]

Contact Adamant Health Oy
Paulus Carpelan
CEO Adamant Health Oy
+358 50 486 7516
[email protected]


About Gerresheimer
Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generated annual revenues in 2021 of around EUR1.5b. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.
www.gerresheimer.com

About Adamant
Adamant Health Ltd. is a research innovation based health technology company focusing on developing and providing measurement and analysis services for Parkinson’s disease and other movement disorders. The novel technology is based on over 15 years of research and clinical tests done at the University of Eastern Finland. Adamant Health’s mission is to bring the research findings for the benefit of people with movement disorders by enabling clinicians, pharma companies and researchers to base their work on objective and detailed real-world patient data measured as part of patients’ daily life.
https://www.adamanthealth.com/



End of Media Release


Issuer: Gerresheimer AG
Key word(s): Enterprise

13.06.2022 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Düsseldorf
Germany
Phone: +49-(0)211/61 81-314
Fax: +49-(0)211/61 81-121
E-mail: [email protected]
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1373719

 
End of News DGAP Media

1373719  13.06.2022 

fncls.ssp?fn=show_t_gif&application_id=1373719&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.348,25 1.367,73 1.392,26 1.418,79 1.498,01 1.817,09 1.990,49
EBITDA1,2 310,83 298,60 400,01 310,14 306,31 340,87 399,42
EBITDA-Marge3 23,05 21,83 28,73 21,86 20,45 18,76
EBIT1,4 180,80 139,46 123,76 156,46 147,44 169,31 213,39
EBIT-Marge5 13,41 10,20 8,89 11,03 9,84 9,32 10,72
Jahresüberschuss1 103,05 131,13 82,68 89,88 87,24 102,19 120,09
Netto-Marge6 7,64 9,59 5,94 6,33 5,82 5,62 6,03
Cashflow1,7 219,16 173,47 192,92 222,19 212,08 221,94 294,34
Ergebnis je Aktie8 3,21 4,11 2,57 2,82 2,67 3,06 3,48
Dividende8 1,10 1,15 1,20 1,25 1,25 1,25 1,05
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
Gerresheimer
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0LD6E 99,500 Halten 3.436,73
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
21,63 23,88 0,91 30,21
KBV KCV KUV EV/EBITDA
2,45 11,68 1,73 10,92
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,25 1,25 1,26 05.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.04.2024 11.07.2024 10.10.2024 22.02.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,39% -0,65% 5,46% 6,65%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Gerresheimer AG  ISIN: DE000A0LD6E6 können Sie bei EQS abrufen


Oberflächen/Verpackung , A0LD6E , GXI , XETR:GXI